|
Ann Rheum Dis 1998;57:701-702 ( December )
Leader
Mixed cryoglobulinaemia after hepatitis C virus: more and
less ambiguity
Article
Since the discovery of the association of hepatitis C virus (HCV) with mixed
cryoglobulinaemia, the use of this term is more ambiguous than ever on the one
hand; on the other hand, there is less ambiguity as 80% of what previously was
classified as essential mixed cryoglobulinaemia (EMC) is now known as secondary
to HCV infection. The ambiguity is generated mainly by the heterogeneity of
mixed cryoglobulins that were originally defined as containing IgG-anti-IgG
(rheumatoid factor (RF)) immune complexes. Early studies focused on these RF
containing mixed cryoglobulins; most of the recent studies, which are predominantly
studies on patients with HCV infection, include cryoglobulins characterised
for mixed isotypes of immunoglobulins but not for RF activity.
Meltzer, Franklin and colleagues1 first coined
the term "mixed cryoglobulins" for the cryoglobulinaemia composed of IgG and
IgM RF that accompanied the syndrome of palpable purpura, arthralgias, and weakness.
Studies performed by Franklin's group and by others implicated the cryoglobulin
components in the immune complex mediated vascular and glomerular lesions that
occur in many patients with this syndrome. The Meltzer-Franklin syndrome, as
it is now called, was also called essential mixed cryoglobulinaemia to distinguish
it from similar mixed cryoglobulinaemia that was known to occur secondary to
a variety of infectious, autoimmune, and malignant diseases.
Shortly after Meltzer et al1 published
their study, the great immunologist, Kunkel2 noted that cryoglobulins might be a sensitive and, by far,
the simplest method for the detection of immune complex because certain complexes
may be soluble at 37°C but precipitate on standing at 4°C. Mixed cryoglobulinaemia
came to imply immune complex disease. This implication was, in fact, true for
the Meltzer-Franklin syndrome because immune complexes, that is, IgG-IgM RF,
were demonstrated in the mixed cryoglobulins, and components of the complex
were demonstrated in the main lesions.
The same admonition that I made 18 years ago for "immune complexes" detected
by the ubiquitous "immune complex assays" of that era3
must be re-stated here even more emphatically for mixed cryoglobulins. Their
presence can be taken only as putative evidence for immune complexes. High molecular
weight immune complexes that can be dissociated into antigen and antibody must
be demonstrated to establish the presence of immune complexes in the mixed cryoglobulins.
To conclude that immune complexes are involved in a disease process, the immune
complexes must be demonstrated in the main lesions of that disease. This may
seem to be an obvious criterion, but it was ignored in the flood of studies
performed using the "immune complex assays" and has been ignored in recent studies
on mixed cryoglobulinaemia. Studies required to delineate immune complexes and
the immune complex disease process are notoriously difficult to perform, and
thus they are avoided. Ambiguity, if not confusion, is the price of this approach.
The biochemical classification of cryoglobulins that is currently widely used
was formulated by Brouet et al4 six years after the description of the Meltzer-Franklin
syndrome. This study, which defined three types of cryoglobulins, was based
on the characterisation of the cryoglobulins from 86 patients who had various
diseases---most with manifestations of immune complex disease. Type I
cryoglobulins consisted of a single isotype of monoclonal immunoglobulins. Type
II cryoglobulins consisted of a mixture of immunoglobulin isotypes with a monoclonal
component processing antibody activity toward polyclonal IgG. The monoclonal
components were predominantly IgM. Type III cryoglobulins consisted of a mixture
of polyclonal immunoglobulins of various isotypes; most of these were also complexes
of polyclonal IgG and polyclonal RF that were mainly IgM. Because RF was a component
of most of the type II and type III cryoglobulins, this study was essentially
a correlation of IgG-IgM RF complexes, with the manifestations of immune complex
diseases.
Recent studies include cryoglobulins characterised for isotypes of immunoglobulins
and monoclonal components but not for RF activity. Only the prevalence of RF
in the serum is usually given. The report in this issue by Lee et al5 is an author-acknowledged example of such a study. In the
degenerate form of the Brouet classification used in this and similar studies,
there is the tacit assumption that if RF is present in the serum it must be
in the cryoglobulin. This assumption may be correct, but the authors did not
indicate the patients who had RF in the serum and whether cryoglobulins were
present in those patients. The end result is that various immunoglobulin isotypes
and monoclonal components are detected in the cryoglobulins, but not even indirect
evidence for immune complexes is provided so that the level of ambiguity generated
is higher than in earlier studies in which at least IgG-IgM RF complexes were
identified.
An example of confusion surrounding mixed cryoglobulins is the different views
of cirrhosis among patients with mixed cryoglobulinaemia held by gastroenterologists
and rheumatologists. Gastroenterologists believe the prevalence of cirrhosis
is higher, whereas the rheumatologist believes it is low. The reason for this
can be gleaned from the two studies compared in figure 1. In the Italian multicentre study,6 the prevalence of cirrhosis among patients with EMC was
significantly lower than that in patients with cryoglobulinaemia secondary to
chronic liver disease (CLD). The French study by Lunel, a gastroenterologist,
and her colleagues7 of patients with mixed cryoglobulinaemia secondary
to CLD found a prevalence of cirrhosis similar to that found for this group
in the Italian study. The ratio of patients with type III to type II cryoglobulinaemia,
which was the reverse of that found in EMC, was similar in the two CLD groups.
|

View Larger
Version
|
Figure 1: Results of the Italian6
and French7 studies are compared. The prevalences of cirrhosis in essential
mixed cryoglobulinaemia (EMC) and in cryoglobulinaemia secondary to chronic
liver disease (2° CLD) are shown. The prevalences of the type of cryoglobulinaemia
(II or III) and rheumatoid factor (RF) and antibodies to hepatitis C virus
antigens (HCV Ab) in the serum are shown for each group. Reprinted from
Agnello V,8 with permission of the publisher. |
Thus, the different "views" result from a patient selection bias. Patients
with EMC similar to those in the Italian multicentre study on presentation frequently
have palpable purpura and other manifestations of systemic vasculitis and are
more likely to be seen by rheumatologists and other specialists than by gastroenterologists.
Patients with CLD have overt liver disease and are seen by the gastroenterologist.
However, these two populations of patients may be associated with distinct types
of mixed cryoglobulins. Unfortunately, the analysis of the cryoglobulins in
the two studies in figure 1 was not sufficient to establish
whether a difference was present beyond the distribution of the cryoglobulin
types. In both of these studies, RF activity in the cryoglobulins was not determined.
In the Italian study and in my review8 of 1033 patients with EMC, palpable purpura was the
most prominent clinical manifestation of mixed cryoglobulinaemia, confirming
the original observation of Meltzer et al. Palpable purpura and other
manifestations of cutaneous vasculitis seem to be the hallmark of a vasculitis
mediated by IgG-IgM RF complexes in mixed cryoglobulins. Recently, HCV has been
demonstrated in the cutaneous vasculitic lesions of patients with type II cryoglobulinaemia.9 Taken together with the earlier finding that HCV was selectively
concentrated in type II cryoglobulins with IgG and IgM RF,10
this finding suggested that the cutaneous vasculitic lesions result from deposition
of complexes of HCV, IgM RF, and IgG.
In most of the cases in the Italian multicentre studies and in our studies
that use sensitive methods for the detection of monoclonal IgM RF (Agnello V,
unpublished data), the cutaneous lesions are associated with type II cryoglobulinaemia,
suggesting that monoclonal IgM RF may be essential for the development of the
cutaneous vasculitic lesions. Immunofixation is routinely used for characterisation
of cryoglobulins. More precise characterisation of the type III cryoglobulins
using the more sensitive technique of immunoblotting11
and the analysis of RF activity of the monoclonal IgM component may determine
that type III cryoglobulins associated with cutaneous vasculitis also contain
a monoclonal IgM RF. Hence, the precise characterisation of the IgM RF in these
cryoglobulins may help define new clinicopathological correlations.
The precise characterisation of cryoglobulins and correlation with clinical
disease are critically needed for mixed cryoglobulins that are mixtures of immunoglobulin
isotypes without RF activity. These mixed cryoglobulins may represent immune
complexes distinct from those containing RF and may be associated with extrahepatic
manifestations of HCV infection that are not associated with RF containing mixed
cryoglobulins, for example, membranous glomerulonephritis or lichen planus.
On the other hand, the immunoglobulins in these cryoglobulins may represent
flotsam from the ineffective immune response to HCV infection that is a feature
of this disease.12 In either instance, precise
characterisation and correlation with clinical disease manifestations of mixed
cryoglobulins may help diminish the ambiguity surrounding mixed cryoglobulinaemia
and perhaps help delineate the role of some of these mixed cryoglobulins in
the extrahepatic manifestations of HCV infection.
VINCENT AGNELLO
Department of Laboratory Medicine, Lahey Clinic Medical Center, Burlington,
Massachusetts, and Edith Nourse Rogers Memorial Veterans Affairs Hospital, Bedford,
Massachusetts, USA
Correspondence to: Dr Agnello, Department of Laboratory Medicine,
Lahey Clinic Medical Center, 41 Mall Road, Burlington, Massachusetts 01805, USA.
REFERENCES
| 1. |
Meltzer M, Franklin EC, Elias K, McCluskey RT, Cooper N.
Cryoglobulinemia: a clinical and laboratory study. II. Cryoglobulins with
rheumatoid factor activity. Am J Med 1966;40:837-856. |
| 2. |
Kunkel HG. Immune complexes and disease. General introduction.
J Exp Med. |
| 3. |
Agnello V. Immune complex assays: The first ten years. Ann
Intern Med 1981;94:266-267. |
| 4. |
Brouet JC, Clauvel JP, Danon F, Klein M, Seligmann M. Biologic
and clinical significance of cryoglobulins: a report of 86 cases. Am
J Med 1974;57:775-788. |
| 5. |
Lee YH, Ji JD, Yeon JE, Byun KS, Lee CH, Song GG. Cryoglobulinaemia
and rheumatic manifestations in patients with hepatitis C virus infection.
Ann Rheum Dis 1998;57:728-731. |
| 6. |
Monti G, Galli M, Invernizzi F, Pioltelli P, Saccardo F,
Monteverde M, et al. Cryoglobulinaemias: a multi-centre study of
the early clinical and laboratory manifestations of primary and secondary
disease. GISC. Italian Group for the Study of Cryoglobulinaemias. Q J Med
1995;88:115-126. |
| 7. |
Lunel F, Musset L, Cacoub P, Frangeul L, Cresta P, Perrin
M, et al. Cryoglobulinemia in chronic liver diseases: role of hepatitis
C virus and liver damage. Gastroenterology 1994;106:1291-1300. |
| 8. |
Agnello V. The etiology and pathophysiology of mixed cryoglobulinemia
secondary to hepatitis C virus infection. Springer Semin Immunopathol 1997;19:111-129. |
| 9. |
Agnello V, Ábel G. Localization of hepatitis C virus
in cutaneous vasculitic lesions in patients with type II cryoglobulinemia.
Arthritis Rheum 1997;40:2007-2015. |
| 10. |
Agnello V, Chung RT, Kaplan LM. A role for hepatitis C virus
infection in type II cryoglobulinemia. N Engl J Med 1992;327:1490-1495. |
| 11. |
Musset L, Diemert MC, Taibi F, Thi Huong Du L, Cacoub P,
Leger JM, et al. Characterization of cryoglobulins by immunoblotting.
Clin Chem 1992;38:798-802. |
| 12. |
Agnello V. Introduction. Springer Semin Immunopathol 1997;19:1-3. |
© 1998 by Annals of the Rheumatic Diseases
|